Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2021) 73 AEP422 | DOI: 10.1530/endoabs.73.AEP422

ECE2021 Audio Eposter Presentations General Endocrinology (51 abstracts)

The effect of COVİD-19 process on patients with endocrinological disease in a pandemic hospital: What Happened to the others?

Evin Bozkur 1 , Seda Turgut 1 , Naim Pamuk 1 , Hamide Piskinpasa 2 , Duygu Metin 3 , Cem Dural 4 , Nuri Alper Sahbaz 4 , Omur Gunaldı 5 , İlkay Cakir 1 , Meral Mert 1 & Sema Ciftci Dogansen 2

1University of Health Sciences, Bakirkoy Dr. Sadi Konuk Training and Research Hospital, Endocrinology and Metabolism, İstanbul, Turkey; 2University of Health Sciences, Bakirkoy Dr. Sadi Konuk Training and Research Hospital, İstanbul, Turkey; 3University of Health Sciences, Bakirkoy Dr. Sadi Konuk Training and Research Hospital, Radiology, İstanbul, Turkey; 4University of Health Sciences, Bakirkoy Dr. Sadi Konuk Training and Research Hospital, Surgery, İstanbul, Turkey; 5University of Health Sciences, Bakirkoy Prof. Dr. Mazhar Osman Training and Research Hospital for Neurology, Neurosurgery and Psychiatry, Department of Neurosurgery, İstanbul, Turkey


To evaluate the effects of the pandemic process on those with an endocrinological disease that will require close follow-up from the last visit before the pandemic.


This was a retrospective study.


Patients of 3903 with thyroid, calcium-bone metabolism, adrenal gland, pituitary diseases, and neuroendocrine tumor (NET) were retrospectively scanned. The remaining 855 (656F/199M) patients with active disease or still needed the multidisciplinary approaches were included in the study. How many patients who continued the disease-related medical procedures could complete these procedures on time in the pandemic period were determined, and the medical deprivation rate (MDR) was calculated.


The pre-pandemic period of our patients with thyroid disease (n = 594), calcium-bone metabolism disorder (n = 130), adrenal disease (n = 85), pituitary disease and NET (n = 46), had MDR 85%, 56%, 81% and 89%, respectively. For each subgroup of the patients; the lowest MDR (67%) was in medullary thyroid carcinoma, the highest MDR (89%) was in differentiated thyroid carcinoma; the lowest MDR (6%) was in osteoporosis, the highest MDR (100%) was in the active Paget’s disease; the lowest MDR (0%) was in primary adrenocortical insufficiency, the highest MDR (100%) was in hyperfunction adrenal adenomas; the lowest MDR (81%) was in the pituitary incidentaloma or non-functional adenomas, and the highest MDR (100%) was in Cushing’s disease, active prolactinoma, TSHoma, and NET, respectively.


This study analyzed the medical deprivations experienced by patients with endocrinological diseases during the pandemic period and showed that these patients’ follow-up and treatment should not be underestimated during the pandemic period.


With the decrease in the number of COVID-19 cases in countries affected by the pandemic, the impact of patients with other diseases who experienced medical deprivation became more prominent.

Volume 73

European Congress of Endocrinology 2021

22 May 2021 - 26 May 2021

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.